Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP2086 (Retagliptin) + Metformin in Type 2 Diabetes
NCT01970046Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Apr 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of retagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Hengrui. Primary endpoint: Change From Baseline in HbA1c (Hemoglobin A1C) at 24 weeks. Status: unknown.
02
Drugs
retagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01970046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01970046.